Literature DB >> 13141233

The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or myleran) upon leukemia.

N L PETRAKIS, H R BIERMAN, K H KELLY, L P WHITE, M B SHIMKIN.   

Abstract

Entities:  

Keywords:  LEUKEMIA/therapy

Mesh：

Substances：

Year:  1954        PMID： 13141233     DOI： 10.1002/1097-0142(195403)7:2<383::aid-cncr2820070225>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  6 in total

1.  [Long-term chemotherapy of chronic myeloid leukemia with Myleran and C69].

Authors:  H EHRHART
Journal:  Klin Wochenschr       Date:  1962-06-15

2.  Medullary aplasia in chronic myeloid leukaemia during busulphan therapy.

Authors:  F G HAYHOE; D KOK
Journal:  Br Med J       Date:  1957-12-21

3.  Myleran in treatment of chronic myeloid leukaemia.

Authors:  E K BLACKBURN; G M KING; H T SWAN
Journal:  Br Med J       Date:  1956-04-14

4.  The chemical control of cancer.

Authors:  J F HOLLAND
Journal:  Public Health Rep       Date:  1954-12       Impact factor: 2.792

5.  Current trends in cancer chemotherapy.

Authors:  B E HALL; F M WILLETT; T V FEICHTMEIR; E B REED; W F DOWLING
Journal:  Calif Med       Date:  1956-01

6.  Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.), 1,2-benzanthracene and beta-propiolactone, as initiators of skin tumour formation in the mouse.

Authors:  F J ROE; M H SALAMAN
Journal:  Br J Cancer       Date:  1955-03       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.